# OnCo record endometrial-mmr-deficient (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/endometrial-mmr-deficient/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "endometrial-mmr-deficient" ;
  schema:name "Mismatch-repair-deficient endometrial cancer"@en ;
  schema:alternateName "dMMR endometrial cancer"@en, "MSI-high endometrial cancer"@en, "MMRd endometrial cancer"@en, "Lynch-associated endometrial cancer"@en ;
  schema:description "Mismatch-repair-deficient endometrial cancer has lost the machinery that corrects copying errors in DNA, so it accumulates thousands of mutations that make it visible to the immune system. Adding dostarlimab or pembrolizumab to chemotherapy in advanced disease cut the risk of progression by about seventy percent, and many patients remain in remission years later."@en ;
  schema:url <https://onco.cc/cancers/endometrial-mmr-deficient/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/trials/nct05173987/>, <https://onco.cc/trials/nct04634877/>, <https://onco.cc/ideas/idea-moon-lynch-vaccine-phase3/>, <https://onco.cc/ideas/idea-bio1-wrn-msi-programme/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:standardOfCare <https://onco.cc/terms/msi/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/endometrial-molecular-classes/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/portec-3/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/trials/ruby/>, <https://onco.cc/trials/nrg-gy018-keynote-868/>, <https://onco.cc/trials/duo-e/>, <https://onco.cc/pairings/chemo-io-first-line-endometrial/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/lynch-syndrome/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/hysterectomy/> .